STRM logo

STRM

STRM is a technology company.

Active
Website LinkedIn X
Updated: ·

About

STRM.BIO develops a non-viral, cell-derived delivery platform for safe, targeted, and scalable in vivo genetic medicines. This core technology employs engineered extracellular vesicles to transport gene therapies, overcoming limitations of traditional viral systems and enhancing treatment precision. The company focuses on developing a more accessible approach to advanced genetic treatments for various conditions.

Jonathan Thon, a serial biotech entrepreneur and leader in human cell culture, founded STRM.BIO. His insight stemmed from the critical need for an effective, scalable gene delivery system to broaden gene therapy applications. Thon, leveraging experience from PlateletBio, established the company to pioneer non-viral delivery platforms and translate scientific advancements into clinical solutions.

STRM.BIO’s platform serves patients globally, particularly those with rare diseases, making gene therapy more accessible. The company’s vision is to democratize gene therapy, ensuring transformative genetic medicines reach a wider population and offer solutions for untreatable conditions. This forward-looking approach aims to reshape the landscape of genetic medicine delivery.

Financial History

STRM has raised $3.0M across 1 funding round.

Total Raised
$3.0M
Valuation
N/A

Frequently Asked Questions

How much funding has STRM raised?

STRM has raised $3.0M in total across 1 funding round.